180 related articles for article (PubMed ID: 25491280)
21. CSF3R is mutated in chronic neutrophilic leukemia and atypical CML.
Cancer Discov; 2013 Jul; 3(7):OF23. PubMed ID: 23847367
[TBL] [Abstract][Full Text] [Related]
22. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent
Gunawan AS; McLornan DP; Wilkins B; Waghorn K; Hoade Y; Cross NCP; Harrison CN
Haematologica; 2017 Jun; 102(6):e238-e240. PubMed ID: 28302714
[No Abstract] [Full Text] [Related]
23. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
Stahl M; Xu ML; Steensma DP; Rampal R; Much M; Zeidan AM
Ann Hematol; 2016 Jun; 95(7):1197-200. PubMed ID: 27068405
[No Abstract] [Full Text] [Related]
24. What's different about atypical CML and chronic neutrophilic leukemia?
Dao KH; Tyner JW
Hematology Am Soc Hematol Educ Program; 2015; 2015():264-71. PubMed ID: 26637732
[TBL] [Abstract][Full Text] [Related]
25. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
Lavallée VP; Krosl J; Lemieux S; Boucher G; Gendron P; Pabst C; Boivin I; Marinier A; Guidos CJ; Meloche S; Hébert J; Sauvageau G
Blood; 2016 Jun; 127(24):3054-61. PubMed ID: 27034432
[TBL] [Abstract][Full Text] [Related]
26. CSF3R-, ASXL1-, and SETBP1-mutated chronic neutrophilic leukemia with monoclonal gammopathy of undetermined significance in a patient who developed severe ascites due to sinusoidal neutrophilic infiltration.
Harada N; Mukai D; Izuta Y; Shibano I; Kizawa Y; Shiragami H; Ohnishi N; Hosaka N; Mugitani A
Pathol Int; 2024 Feb; 74(2):93-95. PubMed ID: 38050833
[No Abstract] [Full Text] [Related]
27. Genomics of chronic neutrophilic leukemia.
Maxson JE; Tyner JW
Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
[TBL] [Abstract][Full Text] [Related]
28. Current and evolving understanding of atypical chronic myeloid leukemia.
Schwartz LC; Mascarenhas J
Blood Rev; 2019 Jan; 33():74-81. PubMed ID: 30078497
[TBL] [Abstract][Full Text] [Related]
29. [CSF3R, ASXL1,SETBP1, JAK2 V617F and CALR mutations in chronic neutrophilic leukemia].
Cui Y; Li B; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1069-73. PubMed ID: 25543699
[TBL] [Abstract][Full Text] [Related]
30. Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.
Hinze A; Rinke J; Hochhaus A; Ernst T
Ann Hematol; 2021 Feb; 100(2):581-584. PubMed ID: 32577845
[No Abstract] [Full Text] [Related]
31. T618I CSF3R mutations in chronic neutrophilic leukemia induce oncogenic signals through aberrant trafficking and constitutive phosphorylation of the O-glycosylated receptor form.
Price A; Druhan LJ; Lance A; Clark G; Vestal CG; Zhang Q; Foureau D; Parsons J; Hamilton A; Steuerwald NM; Avalos BR
Biochem Biophys Res Commun; 2020 Feb; 523(1):208-213. PubMed ID: 31848046
[TBL] [Abstract][Full Text] [Related]
32. Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia.
Adam FC; Szybinski J; Halter JP; Cantoni N; Wenzel F; Leonards K; Brkic S; Passweg JR; Touw I; Maxson JE; Meyer SC
Curr Oncol; 2022 Feb; 29(2):805-815. PubMed ID: 35200567
[TBL] [Abstract][Full Text] [Related]
33. Successful Allogeneic Stem Cell Transplantation with Ruxolitinib Maintenance Therapy for
Ye P; Lin Q; Jin M; Gu X; Lu Y
Turk J Haematol; 2023 Feb; 40(1):73-74. PubMed ID: 36510384
[No Abstract] [Full Text] [Related]
34. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
[TBL] [Abstract][Full Text] [Related]
35. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
36. A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.
Spiciarich DR; Oh ST; Foley A; Hughes SB; Mauro MJ; Abdel-Wahab O; Press RD; Viner R; Thompson SL; Chen Q; Azadi P; Bertozzi CR; Maxson JE
Cancer Res; 2018 Dec; 78(24):6762-6770. PubMed ID: 30348809
[TBL] [Abstract][Full Text] [Related]
37. [Emergence of mutation in the colony-stimulating factor 3 receptor gene during follow-up of unclassifiable myeloproliferative neoplasm].
Harada S; Okada K; Yokoyama S; Hidaka D; Hayase E; Onozawa M; Goto H; Hashimoto D; Kahata K; Endo T; Teshima T
Rinsho Ketsueki; 2021; 62(11):1609-1614. PubMed ID: 34866084
[TBL] [Abstract][Full Text] [Related]
38. The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT.
Langabeer SE; McCarron SL; Haslam K; O'Donovan MT; Conneally E
Bone Marrow Transplant; 2014 Jun; 49(6):843-4. PubMed ID: 24614839
[No Abstract] [Full Text] [Related]
39. [The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia].
Cui YJ; Jiang Q; Liu JQ; Li B; Xu ZF; Qin TJ; Zhang Y; Cai WY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):28-32. PubMed ID: 28219221
[No Abstract] [Full Text] [Related]
40. Current strategies in the diagnosis and management of chronic neutrophilic leukemia.
Otgonbat A; Zhao M
Chin Med J (Engl); 2014; 127(24):4258-62. PubMed ID: 25533830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
